At the MCI stage of AD, longitudinal findings over the course of a nearly 10-year period have shown that CSF levels of Aβ42 were decreased 5 to 10 years prior to progression to AD dementia, whereas T-tau and P-tau appeared to be later markers as baseline levels were significantly higher in those who converted within the first 5 years, as compared to those who converted between five and years [100]. The gene discussed is MAPT; the disease is Alzheimer disease.